ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2022
Surveillance for Lyme disease in Canada, 2009-2019.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Global risk assessment of Lyme borreliosis transmission.Pathogens and global health · 2026Article
- Ticks and tick-borne diseases: A call for comprehensive tick surveillance in India under One Health approach.The Indian journal of medical research · 2026Review
- Changing case definition: An analysis of its impact on Lyme disease surveillance in Nova Scotia.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Surveillance forCanada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Use of administrative data for evaluating trends in medically-attended Lyme disease, Manitoba, Canada, 2010-2021.PloS one · 2026Article
- Lyme disease control 2.0: Advances and opportunities coming with Lyme disease vaccine VLA15.PLoS pathogens · 2025Article
- Article
- Age- and Sex-Specific Differences in Lyme Disease Health-Related Behaviors, Ontario, Canada, 2015-2022.Emerging infectious diseases · 2024Article
- Retrospective validation of a rapid Lyme fluorescent immunoassay in differentiating Lyme arthritis from other musculoskeletal presentations in children in a Lyme-endemic region.Microbiology spectrum · 2024Article
- Distribution and pathogen prevalence of field-collected ticks from south-western Korea: a study from 2019 to 2022.Scientific reports · 2024Article
- Article
- Current and future burden from Lyme disease in Québec as a result of climate change.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Article
- Registered Nurses' Knowledge, Attitudes, and Practices Toward Climate-Sensitive Vector-Borne Diseases: Findings From a Cross-Sectional Survey.Public health nursing (Boston, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lyme disease (LD) is a multisystem infection that can affect the skin, heart, joints and nervous system. In Canada, the incidence of LD cases has increased over the past decade making this a disease of public health concern. The objective of this study is to summarize the epidemiology of LD cases reported in Canada from 2009 through 2019. Methods: Incidence over time, case classification (confirmed and probable), seasonal and geographic distribution, demographic and clinical characteristics of reported LD cases were determined. Logistic regression was used to explore potential demographic risk factors for the occurrence of LD. Results: During 2009-2019, a total of 10,150 LD cases were reported by the provinces to the Public Health Agency of Canada, of which 7,242 (71.3%) were confirmed and 2,908 (28.7%) were probable cases. The annual count increased from 144 in 2009 to 2,634 in 2019, mainly due to an increase in locally acquired infections, from 65.3% to 93.6%, respectively. The majority of cases (92.1%) were reported from three provinces: Ontario (46.0%); Nova Scotia (28.0%); and Québec (18.1%). Most of the locally acquired cases (74.0%) were reported in the summer months of June (20.0%), July (35.4%) and August (18.6%). The highest incidence rates (cases per 100,000 population) were in children aged 5-9 years (45.0) and in adults aged 65-69 years (74.3), with 57.3% of all reported cases occurring among males. The most common presenting symptoms were single erythema migrans rash (75.1%) and arthritis (34.1%). The frequency of reported clinical manifestations varied among age groups and seasons with erythema migrans and arthritis at presentation reported more frequently in children than older patients. Conclusion: The results of this report highlight the continued emergence of LD in Canada and the need for further development and implementation of targeted awareness campaigns designed to minimize the burden of LD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.